FSM Wealth Advisors LLC Has $414,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

FSM Wealth Advisors LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY) by 22.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,592 shares of the biopharmaceutical company’s stock after acquiring an additional 1,195 shares during the quarter. FSM Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $414,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. BlackRock Inc. boosted its holdings in shares of Bristol-Myers Squibb by 1.7% during the first quarter. BlackRock Inc. now owns 175,584,734 shares of the biopharmaceutical company’s stock worth $12,169,778,000 after acquiring an additional 2,856,746 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Bristol-Myers Squibb by 10.3% during the first quarter. Ameriprise Financial Inc. now owns 26,084,266 shares of the biopharmaceutical company’s stock worth $1,807,487,000 after acquiring an additional 2,439,814 shares during the period. Norges Bank bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth approximately $1,873,696,000. Moneta Group Investment Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 114,228.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock valued at $1,544,751,000 after buying an additional 21,451,006 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of Bristol-Myers Squibb by 7.0% in the first quarter. Deutsche Bank AG now owns 19,381,102 shares of the biopharmaceutical company’s stock valued at $1,343,304,000 after buying an additional 1,263,969 shares during the period. Institutional investors and hedge funds own 74.98% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Ann Powell sold 17,986 shares of the firm’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.25, for a total value of $1,101,642.50. Following the completion of the transaction, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at approximately $1,706,915. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Robert M. Plenge sold 732 shares of Bristol-Myers Squibb stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $61.14, for a total transaction of $44,754.48. Following the completion of the sale, the executive vice president now directly owns 6,584 shares of the company’s stock, valued at approximately $402,545.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Ann Powell sold 17,986 shares of Bristol-Myers Squibb stock in a transaction on Thursday, August 24th. The stock was sold at an average price of $61.25, for a total transaction of $1,101,642.50. Following the sale, the executive vice president now directly owns 27,868 shares of the company’s stock, valued at $1,706,915. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

Bristol-Myers Squibb Stock Down 0.7 %

NYSE:BMY traded down $0.39 on Monday, hitting $58.64. The stock had a trading volume of 4,903,311 shares, compared to its average volume of 8,930,969. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.28 and a current ratio of 1.39. The stock has a market cap of $122.50 billion, a P/E ratio of 15.63, a price-to-earnings-growth ratio of 1.57 and a beta of 0.42. Bristol-Myers Squibb has a 1 year low of $58.33 and a 1 year high of $81.43. The firm’s fifty day simple moving average is $61.62 and its two-hundred day simple moving average is $65.11.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, missing analysts’ consensus estimates of $1.99 by ($0.24). Bristol-Myers Squibb had a net margin of 17.62% and a return on equity of 50.51%. The business had revenue of $11.23 billion during the quarter, compared to analysts’ expectations of $11.81 billion. During the same quarter in the prior year, the firm posted $1.93 earnings per share. The firm’s quarterly revenue was down 5.6% on a year-over-year basis. Analysts predict that Bristol-Myers Squibb will post 7.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

BMY has been the subject of several recent analyst reports. Atlantic Securities cut their target price on Bristol-Myers Squibb from $90.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, July 28th. BMO Capital Markets cut their target price on Bristol-Myers Squibb from $87.00 to $79.00 and set an “outperform” rating for the company in a research note on Friday, July 28th. Barclays cut their target price on Bristol-Myers Squibb from $64.00 to $62.00 and set an “equal weight” rating for the company in a research note on Friday, July 28th. Morgan Stanley reiterated an “underweight” rating and set a $59.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, July 19th. Finally, HSBC assumed coverage on shares of Bristol-Myers Squibb in a report on Friday, July 14th. They set a “reduce” rating and a $56.00 price target for the company. Two analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $70.67.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.